Brought to you by 
Tracon could get rights to two Janssen oncology candidates, retains global rights to TRC253
24 Apr 2020
Executive Summary
Janssen Pharmaceutica NV licensed Tracon Pharmaceuticals Inc. rights to develop, manufacture, and commercialize two preclinical cancer compounds--JNJ63576253 (renamed TRC253), an inhibitor of wild type androgen receptor (AR) and multiple AR mutations aimed at prostate cancer; and JNJ64290694 (TRC694), an inhibitor of NF-kB inducing kinase (NIK) for treating hematologic malignancies including myeloma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tracon could get rights to two Janssen oncology candidates, retains global rights to TRC253
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice